Original French opinion adopted by the Transparency Committee.

The legally binding text is the original French opinion version.

SUMMARY

travoprost

TRAVATAN 40 µg/ml

eye drops, solution

Inclusion on list: First listing

Range supplement

Adopted by the Transparency Committee on 10 September 2025

Summary of opinion

Favourable opinion for reimbursement in:

- decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma;
- decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.

No clinical added value of the new form compared to the form already available.

Transparency Committee's conclusions

Clinical Benefit

- Glaucoma in adults is a severe condition that can cause blindness. Glaucoma and ocular hypertension in children are serious conditions that frequently lead to visual impairment and can cause blindness.
- TRAVATAN 40 µg/mL (travoprost) eye drops, solution, packaged in a polyethylene bottle, is a curative treatment for glaucoma in adults. This proprietary medicinal product, as an adjunct to surgery in congenital glaucoma or in combination with causal treatment for secondary glaucoma, is a preventive treatment for the complications of ocular hypertension in children.
- The efficacy/adverse effects ratio is high.
- This is a first or second-line treatment in view of the therapies available for the reduction of elevated intraocular pressure in:
- adult patients with ocular hypertension or open-angle glaucoma;
- paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.

→ Public health benefit

TRAVATAN 40 µg/mL (travoprost) eye drops, solution, packaged in a polyethylene bottle, is unlikely to have an additional impact on public health.

The Committee considers that the clinical benefit of TRAVATAN 40 µg/mL (travoprost) eye drops, solution, packaged in a polyethylene bottle, is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion in the list of covered drugs for outpatients approved for use in the indication and at the MA dosages.

→ Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%

Clinical Added Value

This medicinal product is a range supplement that provides no clinical added value (CAV V) compared to the form already listed.